Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.
Vosevi ihlinzeka inketho ukwelashwa kwezinye iziguli abangabulawanga iphathwa ngempumelelo nezinye izidakamizwa HCV esikhathini esidlule, "kusho u-Edward Cox, MD, umqondisi we-Ofisi Elwa Namagciwane imikhiqizo FDA Centre for Drug nokuHlola Ucwaningo.